Jounce Therapeutics, Inc.

Jounce Therapeutics, Inc.

Jounce Therapeutics, Inc.

Overview
Date Founded

2013

Headquarters

780 Memorial Drive, Cambridge, MA, 02139, USA

Type of Company

Public

Employees (Worldwide)

115

Industries

Biotechnology
Pharmaceuticals
Holding Companies

Company Description

Jounce Therapeutics, Inc. is a clinical stage immunotherapy company, which treat cancer by developing therapies that enable the immune system to attack tumors and provide long-lasting benefits to patients. Its products pipeline include JTX-2011 (ICOS); JTX-4014 (PD-1); Lead Macrophage Program; Macrophage Targeting; T Reg; B Cells; and Stromal Targeting. The company was founded by Louis M. Weiner, Drew M. Pardoll, Thomas F. Gajewski, James P. Allison, Robert Schreiber and Padmanee Sharma in 2013 and is headquartered in Cambridge, MA.

Contact Data
Trying to get in touch with decision makers at Jounce Therapeutics, Inc.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

Founder

Founder

Founder

Founder

Founder

President, Chief Executive Officer & Director

Chief Financial Officer

Chief Medical Officer

Chief Technical Officer

Board of Directors

Intellia Therapeutics, Inc.

Former Chief Financial Officer, Secretary & Treasurer at Intercept Pharmaceuticals, Inc.

Co-Founder at Third Rock Ventures LLC

Former Chief Operating Officer at Agios Pharmaceuticals, Inc.

Co-Founder at Personal Genome Diagnostics, Inc.

President, Chief Executive Officer & Director at Jounce Therapeutics, Inc.

Scientific Advisor at 180 Therapeutics LP

Partner at Third Rock Ventures LLC

Paths to Jounce Therapeutics, Inc.
Potential Connections via
Relationship Science
You
Jounce Therapeutics, Inc.
Owners & Shareholders
Details Hidden

Third Rock invests in early-stage product-focused life science companies, particularly biotechnology, biopharmaceutical and medical device companies. They look for companies with high-growth potential that are well-positioned to bring about change in the marketplace. The firm focuses on transformative life sciences companies in areas of disruptive science likely to make a difference in the lives of patients. Third Rock actively engages with their portfolio companies to provide hands-on support.

Details Hidden

Third Rock invests in early-stage product-focused life science companies, particularly biotechnology, biopharmaceutical and medical device companies. They look for companies with high-growth potential that are well-positioned to bring about change in the marketplace. The firm focuses on transformative life sciences companies in areas of disruptive science likely to make a difference in the lives of patients. Third Rock actively engages with their portfolio companies to provide hands-on support.

Recent Transactions
Details Hidden

Jounce Therapeutics, Inc. issued USD Common Stock

Details Hidden

Jounce Therapeutics, Inc. raised money in a private placement transaction

Transaction Advisors
Escrow Agent

Advised onJounce Therapeutics, Inc. issued USD Common Stock

Underwriter

Advised onJounce Therapeutics, Inc. issued USD Common Stock

Underwriter

Advised onJounce Therapeutics, Inc. issued USD Common Stock

Associate

Advised onJounce Therapeutics, Inc. issued USD Common Stock

Chair, Life Sciences Practice

Advised onJounce Therapeutics, Inc. issued USD Common Stock

Legal Advisor

Advised onJounce Therapeutics, Inc. issued USD Common Stock

Advisors & Consultants
Legal Advisor

Partner at Davis Polk & Wardwell LLP

Legal Advisor

Partner at Davis Polk & Wardwell LLP

Publicist

Founder at 1AB Media

Clients

Celgene is a global biopharmaceutical company committed to improving the lives of patients worldwide. At Celgene, we seek to deliver truly innovative and life-changing drugs for our patients. Our mission as a company is to build a major global biopharmaceutical corporation while focusing on the discovery, the development, and the commercialization of products for the treatment of cancer and other severe, immune, inflammatory conditions. There are more than 300 clinical trials at major medical centers using compounds from Celgene. Investigational compounds are being studied for patients with incurable hematological and solid tumor cancers, including multiple myeloma, myelodysplastic syndromes, chronic lymphocyte leukemia (CLL), non-Hodgkin's lymphoma (NHL), myelofibrosis, small cell lung cancer and prostate cancer. As committed as we are to clinical accomplishment, we are equally committed to patient support, which is a guiding principle at Celgene. We believe all who can benefit from our discoveries should have the opportunity to do so. Celgene puts patients first with industry-leading programs that provide information, support and access to our innovative therapies

Key Stats and Financials As of 2018
Market Capitalization
$125M
Total Enterprise Value
$-80.1M
Earnings Per Share
$-0.84
Revenue
$65.2M
Net Profit
$-27.4M
EBITDA
$-27.5M
EBITDAMargin
-42.12%
Total Debt
$0
Total Equity
$104M
Enterprise Value Sales
-1.23x
TEVNet Income
2.93x
Debt TEV
0x
Investors
Details Hidden

Third Rock invests in early-stage product-focused life science companies, particularly biotechnology, biopharmaceutical and medical device companies. They look for companies with high-growth potential that are well-positioned to bring about change in the marketplace. The firm focuses on transformative life sciences companies in areas of disruptive science likely to make a difference in the lives of patients. Third Rock actively engages with their portfolio companies to provide hands-on support.

Details Hidden

Cormorant invests in companies primarily located in North America. The firm targets companies in sectors such as life-science and biotech. It provides financing for early stage capital requirements.

Details Hidden

Celgene Switzerland SARL, part of Celgene Corp., is a Swiss company located in Boudry. The firm operates as a global biopharmaceutical company.

Suppliers
University of Texas - MD Anderson Cancer Center Medical Support Services | Houston, TX

The University of Texas MD Anderson Cancer Center is one of the world’s most respected centers devoted exclusively to cancer patient care, research, education and prevention. It is located in central Houston in the Texas Medical Center. MD Anderson was created in 1941 as part of The University of Texas System. The institution is one of the nation’s original three comprehensive cancer centers designated by the National Cancer Act of 1971 and is one of 68 National Cancer Institute-designated comprehensive cancer centers today. U.S. News & World Report’s "Best Hospitals" survey has ranked MD Anderson as one of the nation’s top two cancer centers every year since the survey began in 1990.

Memorial Sloan-Kettering Cancer Center Hospitals & Patient Services | New York, NY

Memorial Sloan-Kettering Cancer Center — the world's oldest and largest private cancer center — has devoted more than 125 years to exceptional patient care, innovative research, and outstanding educational programs. Today, we are one of 41 National Cancer Institute–designated Comprehensive Cancer Centers, with state-of-the-art science flourishing side by side with clinical studies and treatment. The close collaboration between our physicians and scientists is one of our unique strengths, enabling us to provide patients with the best care available as we work to discover more-effective strategies to prevent, control, and ultimately cure cancer in the future. Our education programs train future physicians and scientists, and the knowledge and experience they gain at Memorial Sloan-Kettering has an impact on cancer treatment and biomedical research around the world.

Memorial Hospital For Cancer And Allied Diseases Hospitals & Patient Services | New York, NY

Memorial Hospital for Cancer and Allied Diseases care for people with all types of cancer and allied diseases. People can get detailed information about their approach to diagnosis and treatment, doctors who specialize in their type of cancer, and links to related news and resources.

Competitors
Merck & Co., Inc. Pharmaceuticals - Kenilworth, NJ

Merck & Co., Inc. , d.b.a. Merck Sharp & Dohme, MSD outside the United States and Canada, is an American pharmaceutical company and is one of the largest pharmaceutical companies in the world.

Regeneron Pharmaceuticals, Inc. Pharmaceuticals - Tarrytown, New York

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. It product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988 and is headquartered in Tarrytown, NY.

GlaxoSmithKline Plc Pharmaceuticals - Brentford, Middlesex

GlaxoSmithKline Plc is a global healthcare company which engages in researching, developing and manufacturing of pharmaceutical medicines, vaccines and consumer healthcare products. It operates through the following four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines and Consumer Healthcare. The Pharmaceuticals segment researches, develops and makes available medicines that treat a variety of serious and chronic diseases. The Vaccines segment produces pediatric and adult vaccines to prevent a range of infectious diseases including, hepatitis A and B, diphtheria, tetanus and whooping cough, measles, mumps and rubella, polio, typhoid, influenza and bacterial meningitis. The Consumer Healthcare segment markets a range of consumer health products based on scientific innovation. The company was founded in 1715 and is headquartered in Brentford, the United Kingdom.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Jounce Therapeutics, Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Jounce Therapeutics, Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and Jounce Therapeutics, Inc..